Terms: = Lung cancer AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK AND Clinical Outcome
69 results:
1. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract] [Full Text] [Related]
2. [clinical analysis of lung adenocarcinoma with epidermal growth factor receptor mutation transformed into sarcoma].
Zhu QQ; Du MZ; Wu WT; Guo LC; Huang JA; Shen D
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Jan; 47(1):24-30. PubMed ID: 38062690
[No Abstract] [Full Text] [Related]
3. clinical outcomes of
Hansen KH; Johansen JS; Urbanska EM; Meldgaard P; Hjorth-Hansen P; Kristiansen C; Stelmach M; Santoni-Rugiu E; Ulhøi MP; Dydensborg AB; Dünweber C; Andersen JL
Acta Oncol; 2023 Dec; 62(12):1775-1783. PubMed ID: 37815923
[TBL] [Abstract] [Full Text] [Related]
4. ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue.
Mersiades AJ; Solomon BJ; Thomas DM; Lee CK; Cummins MM; Sebastian L; Ballinger ML; Collignon E; Turnbull OM; Yip S; Morton RL; Brown C; Wheeler PJ; Itchins M; Simes RJ; Pavlakis N
Future Oncol; 2024 Mar; 20(7):361-371. PubMed ID: 37767626
[TBL] [Abstract] [Full Text] [Related]
5. The evolution of lung cancer and impact of subclonal selection in TRACERx.
Frankell AM; Dietzen M; Al Bakir M; Lim EL; Karasaki T; Ward S; Veeriah S; Colliver E; Huebner A; Bunkum A; Hill MS; Grigoriadis K; Moore DA; Black JRM; Liu WK; Thol K; Pich O; Watkins TBK; Naceur-Lombardelli C; Cook DE; Salgado R; Wilson GA; Bailey C; Angelova M; Bentham R; Martínez-Ruiz C; Abbosh C; Nicholson AG; Le Quesne J; Biswas D; Rosenthal R; Puttick C; Hessey S; Lee C; Prymas P; Toncheva A; Smith J; Xing W; Nicod J; Price G; Kerr KM; Naidu B; Middleton G; Blyth KG; Fennell DA; Forster MD; Lee SM; Falzon M; Hewish M; Shackcloth MJ; Lim E; Benafif S; Russell P; Boleti E; Krebs MG; Lester JF; Papadatos-Pastos D; Ahmad T; Thakrar RM; Lawrence D; Navani N; Janes SM; Dive C; Blackhall FH; Summers Y; Cave J; Marafioti T; Herrero J; Quezada SA; Peggs KS; Schwarz RF; Van Loo P; Miedema DM; Birkbak NJ; Hiley CT; Hackshaw A; Zaccaria S; ; Jamal-Hanjani M; McGranahan N; Swanton C
Nature; 2023 Apr; 616(7957):525-533. PubMed ID: 37046096
[TBL] [Abstract] [Full Text] [Related]
6. Resistance to immune checkpoint inhibitors in advanced lung cancer: clinical characteristics, potential prognostic factors and next strategy.
Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
[TBL] [Abstract] [Full Text] [Related]
7. Genomic Characteristics and the Potential clinical Implications in Oligometastatic Non-Small Cell lung cancer.
Liao R; Chen K; Li J; He H; Yi G; Huang M; Chen R; Shen L; Zhang X; Xu Z; Yang Z; Peng Y
Cancer Res Treat; 2023 Jul; 55(3):814-831. PubMed ID: 36634615
[TBL] [Abstract] [Full Text] [Related]
8. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients.
Li D; Jiang H; Jin F; Pan L; Xie Y; Zhang L; Li C
Genes Genomics; 2023 Jan; 45(1):93-102. PubMed ID: 36445572
[TBL] [Abstract] [Full Text] [Related]
9. Detection of alk fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with alk-TKI sequences.
Tabbò F; Muscarella LA; Gobbini E; Trombetta D; Castellana S; Rigutto A; Galetta D; Maiello E; Martelli O; Tiseo M; Scotti V; Ghilardi L; Gregorc V; Sergi C; Pilotto S; Del Conte A; Cappuzzo F; Cortinovis D; Osman G; Bareggi C; Di Maio M; Rossi A; Rossi G; Bria E; Volante M; Scagliotti GV; Graziano P; Novello S; Righi L
Eur J Cancer; 2022 Oct; 174():200-211. PubMed ID: 36044814
[TBL] [Abstract] [Full Text] [Related]
10. Ranking the most influential predictors of CT-based radiomics feature values in metastatic lung adenocarcinoma.
Crombé A; Lafon M; Nougaret S; Kind M; Cousin S
Eur J Radiol; 2022 Oct; 155():110472. PubMed ID: 35985090
[TBL] [Abstract] [Full Text] [Related]
11. Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes.
Yao Y; Yu Z; Ma Y; Ou Q; Wu X; Lu D; Li X
ESMO Open; 2022 Apr; 7(2):100405. PubMed ID: 35305401
[TBL] [Abstract] [Full Text] [Related]
12. Synchronous lung and multiple soft tissue metastases developed from osteosarcoma of tibia: a rare case report and genetic profile analysis.
Zheng C; Wang Y; Luo Y; Pang Z; Zhou Y; Min L; Tu C
BMC Musculoskelet Disord; 2022 Jan; 23(1):74. PubMed ID: 35057767
[TBL] [Abstract] [Full Text] [Related]
13. Genetic landscape of patients with alk-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.
Tan DS; Thomas M; Kim DW; Szpakowski S; Urban P; Mehra R; Chow LQM; Sharma S; Solomon BJ; Felip E; Camidge DR; Vansteenkiste J; Petruzzelli L; Pantano S; Shaw AT
Lung Cancer; 2022 Jan; 163():7-13. PubMed ID: 34890832
[TBL] [Abstract] [Full Text] [Related]
14. clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced alk+NSCLC: A multicenter retrospective analysis in China.
Zou Z; Hao X; Zhang C; Li H; Dong G; Peng Y; Ma K; Guo Y; Shan L; Zhang Y; Liang L; Gu Y; Xing P; Li J
Thorac Cancer; 2022 Jan; 13(1):107-116. PubMed ID: 34851035
[TBL] [Abstract] [Full Text] [Related]
15. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract] [Full Text] [Related]
16. Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non-small cell lung cancer.
Hou D; Zheng X; Song W; Liu X; Wang S; Zhou L; Tao X; Lv L; Sun Q; Jin Y; Zhang Z; Ding L; Wu N; Zhao S
Thorac Cancer; 2021 Sep; 12(17):2388-2399. PubMed ID: 34288491
[TBL] [Abstract] [Full Text] [Related]
17. Brigatinib versus other second-generation alk inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
Christopoulos P; Bozorgmehr F; Brückner L; Chung I; Krisam J; Schneider MA; Stenzinger A; Eickhoff R; Mueller DW; Thomas M
BMC Cancer; 2021 Jun; 21(1):743. PubMed ID: 34182952
[TBL] [Abstract] [Full Text] [Related]
18. Anaplastic lymphoma kinase tyrosine kinase inhibitor-induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database.
Zhou Z; Wang C; Ying L; Jin M; Zhang F; Shi D
J Clin Pharm Ther; 2021 Aug; 46(4):1148-1154. PubMed ID: 33768534
[TBL] [Abstract] [Full Text] [Related]
19. Distribution and therapeutic outcomes of intergenic sequence-alk fusion and coexisting alk fusions in lung adenocarcinoma patients.
Cai C; Tang Y; Li Y; Chen Y; Tian P; Wang Y; Gong Y; Peng F; Zhang Y; Yu M; Wang K; Zhu J; Lu Y; Huang M
Lung Cancer; 2021 Feb; 152():104-108. PubMed ID: 33444901
[TBL] [Abstract] [Full Text] [Related]
20. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
[TBL] [Abstract] [Full Text] [Related]
[Next]
